




RealRate

PHARMACEUTICAL 2018

Astria Therapeutics Inc. Rank 277 of 342





PHARMACEUTICAL 2018

Astria Therapeutics Inc.
Rank 277 of 342



The relative strengths and weaknesses of Astria Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Astria Therapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Astria Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 131% points.

The company's Economic Capital Ratio, given in the ranking table, is -59%, being 105% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	17,463
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,016
Liabilities, Non-Current	0
Other Assets	113
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	89
Other Net Income	-270
Other Revenues	500
Property and Equipment	321
Research and Development	18,682
Selling, General and Administrative Expense	8,912

Output Variable	Value in 1000 USD
Assets	17,897
Liabilities	6,105
Expenses	27,594
Revenues	500
Stockholders Equity	11,792
Net Income	-27,364
Comprehensive Net Income	-27,364
Economic Capital Ratio	-59%